Sepsis Diagnostics: Market Forecasts by Assay, Cause, Product, Place and Country with Analysis and Executive Guides 2025-2029
Sepsis Diagnostics Markets | Global coverage | Market size | Actionable insights| Trends | Key companies | Growth forecasts
Over 45 million people annually suffer from sepsis without a definitive diagnostic tool. The current race leverages genomic and molecular diagnostic advancements of the past decade. The question arises: Will Artificial Intelligence shape this landscape? The competition is fierce with global implications, offering lucrative opportunities in emergency life-saving diagnostics.
The market outlook predicts significant growth over the next five years, driven by enhanced healthcare standards worldwide. The aftermath of the pandemic has reshaped the realm of respiratory infections, setting the stage for groundbreaking diagnostic technologies. As some players establish their presence, disruptive innovations could redefine the industry dynamics. Explore the evolving market landscape, addressing key trends like Rapid Diagnostics and the Genomics Revolution, which are converging to unveil novel diagnostic pathways.
Our commitment to factual insights ensures your success in navigating this intricate market terrain. Stay informed about the ever-evolving diagnostic sector, understanding the pivotal shifts and future prospects. Embrace the transformative potential of cutting-edge diagnostic solutions, poised to revolutionize healthcare diagnostics globally.
Dive deep into the evolving market dynamics with our comprehensive report, empowering you to become the expert in your organization. Our team is on standby to assist you in leveraging the report effectively, with no added costs for support or additional country data. Excel-formatted data is available upon request, enabling confident investment decisions and valuations backed by the latest insights.
This latest report delves into the Sepsis Diagnostics market from 2025 to 2029, offering valuable insights including:
- Overview of the sepsis diagnostics market structure
- Analysis of healthcare spending
- Examination of market trends
- Identification of factors propelling growth
- Exploration of factors hindering growth
- Recent advancements in sepsis diagnostics
- Profiles of key companies in the sepsis diagnostics sector
The report presents global market forecasts for sepsis diagnostics across various segments:
- Country: USA, Canada, Germany, France, UK, rest of Europe, Japan, China, South Korea, rest of APAC, Brazil, Mexico, rest of LATAM, Middle East and Africa, Global
- Assay: Microbiology, PCR, Immunoassay, Infectious Disease Other, Biomarker MDx, Biomarker Other
- Cause: Gastrointestinal, Repiratory COVID-19, Respiratory Other, Neonatal, Other
- Product: Instumentation, Consumables, Software and Service
- Place: In Lab, Hospital, Point of Care, Other
This comprehensive analysis offers a detailed outlook on the market landscape, providing essential information for stakeholders across different sectors.
This latest report delves into the Sepsis Diagnostics market from 2025 to 2029, offering valuable insights including:
- Overview of the sepsis diagnostics market structure
- Analysis of healthcare spending
- Examination of market trends
- Identification of factors propelling growth
- Exploration of factors hindering growth
- Recent advancements in sepsis diagnostics
- Profiles of key companies in the sepsis diagnostics sector
The report presents global market forecasts for sepsis diagnostics across various segments:
- Country: USA, Canada, Germany, France, UK, rest of Europe, Japan, China, South Korea, rest of APAC, Brazil, Mexico, rest of LATAM, Middle East and Africa, Global
- Assay: Microbiology, PCR, Immunoassay, Infectious Disease Other, Biomarker MDx, Biomarker Other
- Cause: Gastrointestinal, Repiratory COVID-19, Respiratory Other, Neonatal, Other
- Product: Instumentation, Consumables, Software and Service
- Place: In Lab, Hospital, Point of Care, Other
This comprehensive analysis offers a detailed outlook on the market landscape, providing essential information for stakeholders across different sectors.
Pricing options
- $6,995: single-user (encrypted file - one user/device)
- $10,495: multi-user (encrypted file - up to 5 users/devices)
- $13,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in York, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that publications meet the expectations of our demanding customers.
1928 Diagnostics
Abacus Diagnostica
Abbott Laboratories
Accelerate Diagnostics
Access Bio
Ador Diagnostics
ADT Biotech
Akonni Biosystems
Altona Diagnostics
Alveo Technologies
Anatolia Geneworks
Anitoa
Antelope Dx
Applied BioCode
Assurance Scientific Laboratories
Aureum Diagnostics
Aus Diagnostics
Beckman Coulter Diagnostics
Becton, Dickinson and Company
Binx Health
Biocartis
BioFire Diagnostics (bioMérieux)
bioMérieux Diagnostics
Bio-Rad Laboratories
Bosch Healthcare Solutions
Celemics
Cepheid (Danaher)
Chembio
Co Diagnostics
Credo Diagnostics Biomedical
Cue Health
Curetis
Detect
Diagenode Diagnostics
Diascopic
Diasorin
Domus Diagnostics
Eiken Chemical
Element Biosciences
Enzo Biochem
Eurofins Scientific
Fluxergy
Fulgent Genetics
Fusion Genomics
Genedrive
Genetic Signatures
GenMark Dx (Roche
Genomadix
Grifols
Grip Molecular Technologies
Hibergene Diagnostics
Hologic
Illumina
Immunexpress
Inflammatix
Invetech
Janssen Diagnostics
Karius
Lexagene
LightDeck Diagnostics
Lucira Health
Luminex Corp (DiaSorin)
LumiraDx
Lumos Diagnostics
Mammoth Biosciences
Maxim Biomedical
Meridian Bioscience
Mesa Biotech (Thermo Fisher)
MicroGem
Millipore Sigma
Mindray
Minute Molecular
Mobidiag (Hologic)
Molbio Diagnostics
NanoDx
Nanomix
Novacyt
Novel Microdevices
OnsiteGene
Operon
Oxford Nanopore Technologies
Panagene
Pathogenomix
PerkinElmer
Prenetics
Primerdesign (Novacyt)
Prominex
Proof Diagnostics
QIAGEN
QuantuMDx
Quest Diagnostics
QuidelOrtho
Randox Toxicology
Roche Molecular Diagnostics
Saw Diagnostics
Scope Fluidics
SD Biosensor
Seegene
Siemens Healthineers
Singular Genomics
SomaLogic
Sona Nanotech
SpeeDx
T2 Biosystems
Talis Biomedical
Thermo Fisher Scientific
Ultima Genomics
Vela Diagnostics
Veramarx
Veredus Laboratories
Vircell
Visby Medical
XCR Diagnostics
YD Diagnostics
Zhejiang Orient Gene Biotech
Methodology
This report is based on research conducted over the last four months. Data is derived primarily from executive comments, quarterly reports, and industry association data. While much information is kept confidential by suppliers this report infers revenues based on estimates of individual company activities by channel historically, currently, and as intermittently reported. This report aggregates supplier revenues and compares these to industry and other sources to arrive at estimates of current and historical market size. Forecasts are firstly based on historical growth rates and the current overall economic growth outlook for specific regions and countries. Secondarily the growth outlook is modified to account for factors specific to the market under study as
explained in the Situation Analysis.
Sources
Sources of information include the World Health Organization, the International Monetary Fund, the World Bank, several U.S. and European Union government bodies and industry associations. Considerable primary information is collected from company annual and quarterly reports, industry associations, industry participants and executives, whose information and insight are regularly solicited. Much company information comes from company websites, investor presentations, press releases, annual reports, 10K filings, news reports, national statistical services and industry blogs. Technical information is primarily based on published academic literature.
Author
The principal author of this report holds a M.B.A. in Finance and Strategy from the University of British Columbia. He also holds a B.Sc. in Chemistry
from the same university. He is a graduate of the Harvard Business School program Finance for Senior Executives. He is a graduate of The Burke Institute Seminar in Market Research. He has worked in clinical laboratory research and testing in a hands-on capacity. He is a co-author of the paper The Radioimmunoassay of Angiotensinogen II by Antibody Trapping. He has considerable experience in mergers, acquisitions, and business development.
